Clinical Trial

UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies

Study acronym: UKK-0018
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study will test a new investigational treatment called UKK-0018. UKK-0018 as an immunotherapeutic for the treatment of peanut allergies. The treatment is given by injection and is designed to train the immune system to tolerate peanut exposure over time.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-03-31
notable Trial sites expanded: 2 -> 5 locations 2026-03-31
Trial Details
NCT Number NCT07349212
Lead Sponsor Ukko Inc
Conditions Peanut-Induced Anaphylaxis, Peanut Allergy
Enrollment 40 participants
Start Date 2026-02-18
Primary Completion 2027-03-01 (estimated)
Study Completion 2027-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-25